Ranbaxy launches generic version of 'Caduet' in US
The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol.
"Ranbaxy is making available the full range of the generic version of Caduet (as part of an agreement with Pfizer Inc)," it said in a statement.
Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate (presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin).
Caduet generated total annual sales of 339 million dollars in the US (IMS--MAT September 2011).
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Ltd, is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system. (UNI -Posted on / )
More from pharmaceutical-news: